
Ademi LLP Probes Crinetics Pharmaceuticals Valuation in Vertex Deal
Shareholders of Crinetics Pharmaceuticals are under scrutiny as Milwaukee-based Ademi LLP investigates whether the company’s $10 billion acquisition by Vertex delivers fair value. The inquiry centers on allegations that internal change-of-control arrangements may prioritize executive interests over those of public investors.









,regionOfInterest=(1235,656)&hash=4756a5948aa5a3dd50a303b8254fc8021ea1b8e066df5f3cd20e8c0635b93da2)














